<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149706</url>
  </required_header>
  <id_info>
    <org_study_id>Immune Response 2020</org_study_id>
    <nct_id>NCT02149706</nct_id>
  </id_info>
  <brief_title>A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis</brief_title>
  <official_title>A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Response BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>cro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immune Response BioPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study
      of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 150 subjects with Secondary
      Progressive SPMS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare between treatment groups the Measures of neurologic
      disability EDSS scores.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 9, 2020</start_date>
  <completion_date type="Anticipated">March 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to compare between treatment groups the Measures of neurologic disability EDSS score</measure>
    <time_frame>48 Weeks</time_frame>
    <description>The primary objective is to compare between treatment groups the Measures of neurologic disability EDSS scores improvements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary measurements objectives immunologic evaluations</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Secondary measurements objectives immunologic evaluations increases in white blood cell counts &amp; FOXP+3 expression increases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>NeuroVax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NeuroVax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFA Incomplete Freund's Adjuvant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Incomplete Freund's Adjuvant IFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeuroVax</intervention_name>
    <description>NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA</description>
    <arm_group_label>NeuroVax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IFA Incomplete Freund's Adjuvant</intervention_name>
    <description>IFA Placebo Incomplete Freund's Adjuvant</description>
    <arm_group_label>IFA Incomplete Freund's Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages Eligible for Study: 18 Years to 70 Years

          -  Genders Eligible for Study: Both

          -  Accepts Healthy Volunteers: No Criteria

          -  Subject is between 18 and 70 years of age, inclusive.

          -  Definite MS by the revised McDonald criteria (2005) (Appendix A), with a Secondary
             Progressive course.

          -  Expanded Disability Status Scale (EDSS) &gt;=score 3.5 (Appendix B).

          -  Two or more documented clinical relapses of MS in the preceding 24 months OR one
             documented clinical relapse of MS in the preceding 1 2 months prior to screening .

          -  Laboratory values within the following limits:

          -  Creatinine 1 . 5 x high normal.

          -  Hemoglobin

        Exclusion Criteria:

          -  Subjects currently prescribed Campath or Lemtrada
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Bartholomew, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Immune Response BioPharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard M Bartholomew, Ph.D</last_name>
    <phone>1-858-414-4664</phone>
    <email>Richardmbartholomew@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Bartholomew</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRO</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92129</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard M Bartholomew, PhD</last_name>
      <phone>858-414-4664</phone>
      <email>Richardmbartholomew@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Richard Bartholomew, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.immuneresponse.net</url>
    <description>Immune Response BioPharma, Inc.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 24, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Progress Multiple Sclerosis</keyword>
  <keyword>SPMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>NeuroVax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

